Age-related Macular Degeneration (AMD) Market

Global Age-related Macular Degeneration (AMD) Market Report: By Type (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales), and Region (North America, Europe, Asia-Pacific, Latin America, Middle-East and Africa) Global Industry Analysis, Size, Share, Growth, Trends, Regional Analysis, Competitor Analysis and Forecast 2024-2032.

Pharma & Healthcare | January 2024 | Report ID: EMR00481 | Pages: 301

Global Age-related Macular Degeneration (AMD) market is predicted to reach approximately USD 16.83 billion by 2032, at a CAGR of 8.21% from 2024 to 2032.

Age-related Macular Degeneration (AMD) is a progressive eye condition characterized by the deterioration of the macula, a small area in the center of the retina responsible for sharp, central vision. This degenerative process primarily affects individuals aged 50 and older, leading to a gradual loss of central vision and potentially severe visual impairment. AMD is categorized into two types: dry AMD, marked by the accumulation of drusen (yellow deposits) in the macula, and wet AMD, characterized by the growth of abnormal blood vessels beneath the macula, often resulting in leakage and scarring.

Because of rising awareness, an ageing population, and improvements in diagnostic and treatment technologies, the global market for age-related macular degeneration has grown significantly in recent years. To address the unmet medical needs of AMD patients, major players in the market are actively developing novel treatment approaches, such as gene therapies and anti-VEGF therapies. Research and development efforts targeting the exploration of possible biomarkers for early detection and customised treatment approaches are also on the rise in the market.



Global Age-related Macular Degeneration (AMD) report scope and segmentation.

Report Attribute


Estimated Market Value (2023)

USD 8.27 billion

Projected Market Value (2032)

USD 16.83 billion

Base Year


Forecast Years

2024 – 2032

Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Based on By Type, By End-User, Distribution Channel & Region.

Segments Covered

By Type, By End-User, Distribution Channel & By Region.

Forecast Units

Value (USD Billion or Million), and Volume (Units)

Quantitative Units

Revenue in USD million/billion and CAGR from 2024 to 2032.

Regions Covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Countries Covered

U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others.

Report Coverage

Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis.

Delivery Format

Delivered as an attached PDF and Excel through email, according to the purchase option.


Global Age-related Macular Degeneration (AMD) dynamics

The aging global population is a primary driver, as individuals aged 50 and above, who are more susceptible to AMD, constitute a growing demographic. Additionally, the increasing prevalence of lifestyle-related factors, such as poor diet and sedentary lifestyles, contributes to the rising incidence of AMD. Technological advancements in diagnostic tools, such as optical coherence tomography (OCT) and fundus imaging, enable early detection and monitoring, fostering market growth.

In terms of therapeutics, ongoing R&D initiatives to introduce cutting-edge treatment modalities are driving the market. Wet AMD management is dominated by anti-VEGF therapies, with new drug candidates being explored in ongoing clinical trials. The industry's dedication to expanding treatment options is demonstrated by the emergence of gene therapies, regenerative medicine, and combination therapies as viable paths forward. There are still issues, though, such as the high expense of medical care, the difficulty in accessing cutting-edge therapies, and the requirement for personalised medicine techniques. These elements give market participants the chance to investigate pricing tactics, broaden their consumer base, and work together on projects that improve patient accessibility and affordability. In general, the AMD market is defined by the dynamic interaction of changing demographics, advances in technology, and novel therapeutics, requiring industry participants to be flexible and strategically positioned.


Global Age-related Macular Degeneration (AMD) drivers

  • Aging Population and Increased Incidence of AMD

The market for age-related macular degeneration (AMD) is heavily influenced by the growing number of people over 50 in the world. Given that age is the main risk factor for AMD, the number of elderly people in the population is growing, which adds to the condition's increased prevalence. The market is growing as a result of this shift in demographics, which increases demand for AMD diagnostics and treatments. The growing number of possible patients emphasises how crucial it is to carry out more research and development to meet the unique requirements of this elderly population.

  • Technological Advancements in Diagnosis and Treatment

The market for AMD is largely driven by ongoing developments in diagnostic technologies, including fundus imaging and optical coherence tomography (OCT). These instruments facilitate prompt intervention by enabling early detection, precise diagnosis, and tracking of AMD progression. Furthermore, advancements in therapeutic approaches, specifically the triumph of anti-VEGF medications, have revolutionised the field of managing AMD. The emergence of regenerative medicine and gene therapies expands the range of available treatments and opens up new directions for individualised and focused care. The ongoing development of these technologies boosts AMD diagnosis and treatment efficacy and efficiency, which supports market growth.



  • High Treatment Costs and Limited Accessibility

The market growth is severely limited by the high cost of AMD treatments, especially anti-VEGF therapies. There are differences in the availability of treatment due to the financial strain on patients and healthcare systems that restricts access to these cutting-edge therapies. For market participants, addressing the affordability issue is critical. To guarantee that more patients have access to state-of-the-art AMD treatments, strategic pricing models, partnerships, and advocacy initiatives are needed.

  • Long-term Management Challenges

AMD requires ongoing care, including ongoing therapeutic interventions and routine monitoring. This creates problems for patient adherence and puts a burden on medical resources needed for ongoing treatment administration and follow-up. The intricacy of long-term care is increased by the frequent injections required by anti-VEGF treatments. To improve treatment adherence and lessen the burden on patients and healthcare systems, overcoming these obstacles requires creating more practical and patient-friendly treatment regimens in addition to innovations in sustained-release formulations.



  • Personalized Medicine and Targeted Therapies

The emerging field of personalized medicine offers a significant opportunity for the AMD market. As our understanding of the genetic and molecular basis of AMD expands, there is a growing potential for developing targeted therapies tailored to individual patient profiles. Precision medicine approaches can optimize treatment outcomes by considering genetic factors, biomarkers, and patient-specific characteristics, leading to more effective and personalized interventions for AMD.


Segment Overview

  • By Type  

The market is classified into two primary types of AMD: Dry AMD and Wet AMD. Dry AMD is characterized by the gradual deterioration of light-sensitive cells in the macula, leading to a slow and progressive loss of central vision. On the other hand, Wet AMD involves the abnormal growth of blood vessels beneath the macula, leading to a more rapid and severe decline in vision. Both types present unique challenges in terms of diagnosis, treatment, and patient care, necessitating targeted approaches for each subtype.

  • By End User

The end-user segment encompasses a diverse range of healthcare settings where AMD diagnosis and treatment take place. This includes Hospitals, where a comprehensive range of medical services are provided; Specialty Clinics, which focus specifically on ophthalmic care and AMD management; Ambulatory Surgical Centers, offering outpatient surgical procedures related to AMD; Home Healthcare, facilitating patient care within the comfort of their homes; and Others, representing various healthcare facilities involved in AMD management. Each end-user category plays a crucial role in delivering AMD-related services, emphasizing the need for tailored strategies to meet the specific requirements of each setting.

  • By Distribution Channel

The distribution channel segment highlights the pathways through which AMD-related products and treatments reach end-users. Direct Tender involves procurement processes initiated by healthcare institutions to directly acquire medications and services. Retail Sales encompass over-the-counter purchases made by consumers seeking AMD-related products from pharmacies or other retail outlets. Efficient distribution channels are essential to ensure timely access to AMD treatments, and understanding the dynamics of these channels is vital for optimizing the reach and impact of AMD management solutions.


Global Age-related Macular Degeneration (AMD) Overview by Region

In North America, the market is characterized by a high prevalence of AMD cases, driven by an aging population and advanced diagnostic capabilities. The presence of well-established healthcare facilities, coupled with substantial investments in research and development, positions North America as a key player in the AMD market. Europe follows a similar trajectory, with a significant aging population contributing to a rising incidence of AMD. Access to advanced medical technologies and robust healthcare systems in Western European countries further amplifies the regional market's growth.

Asia-Pacific emerges as a dynamic market for AMD, driven by the increasing elderly population, changing lifestyle factors, and improving healthcare infrastructure. Rapid urbanization and lifestyle shifts contribute to the rising prevalence of AMD in countries like China and India. Additionally, the Asia-Pacific region witnesses a surge in healthcare awareness and adoption of advanced treatments, fostering market expansion. In contrast, Latin America and the Middle East & Africa regions face unique challenges, including limited access to healthcare services and lower awareness levels about AMD. However, growing efforts to enhance healthcare infrastructure and raise awareness about eye health are gradually influencing the market dynamics in these regions.



Global Age-related Macular Degeneration (AMD) market competitive landscape

Leading pharmaceutical companies such as Novartis, Roche, and Regeneron Pharmaceuticals play a pivotal role in driving innovation and dominating the AMD therapeutics sector. These companies focus on research and development activities to introduce novel drugs and therapies, often leveraging partnerships with academic institutions and smaller biotech firms to bolster their pipelines.

In addition to pharmaceutical giants, medical device manufacturers like Bausch + Lomb and Genentech contribute significantly to the competitive landscape, developing cutting-edge diagnostic tools and equipment for early AMD detection and precise monitoring. The competitive scenario is further enriched by the presence of specialized biotechnology firms, such as Ophthotech Corporation and Apellis Pharmaceuticals, dedicated to addressing specific challenges associated with AMD treatment. These companies often emphasize targeted therapeutic approaches, including gene therapies and complement inhibition, showcasing the industry's commitment to diversifying treatment modalities.


Global Age-related Macular Degeneration (AMD) Recent Developments

  • Dec 2023, TruTag Technologies, Inc. and Spinnaker Biosciences, Inc. have recently formed a strategic supply partnership. This collaboration aims to leverage TruTag's advanced nano-porous silica (pSi) particles in the development and commercialization of Spinnaker's innovative therapy designed for treating age-related macular degeneration (AMD).
  •  Aug 2023, Astellas Pharma Inc. led by President and CEO Naoki Okamura, announced today that the U.S. Food and Drug Administration (FDA) has granted approval for IZERVAY (avacincaptad pegol intravitreal solution) as a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) on August 4, 2023. IZERVAY, a novel complement C5 inhibitor, stands out as the sole GA treatment endorsed by the FDA, demonstrating a statistically significant reduction (p<0.01) in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials.


Scope of global Age-related Macular Degeneration (AMD) report

Global Age-related Macular Degeneration (AMD) report segmentation



By Type  

  • Dry AMD
  • Wet AMD

By End User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Home Healthcare
  • Others

By Distribution Channel

  • Direct Tender
  • Retail Sales

By Geography

  • North America (USA, and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Russia and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

Customization Scope

  • Available upon request


  • Available upon request


Objectives of the Study

The objectives of the study are summarized in 5 stages. They are as mentioned below:

  • Global Age-related Macular Degeneration (AMD) size and forecast:To identify and estimate the market size for global Age-related Macular Degeneration (AMD) market segmented by Type, By End-User, Distribution Channel and by region. Also, to understand the consumption/ demand created by consumers between 2024 and 2032.
  • Market Landscape and Trends: To identify and infer the drivers, restraints, opportunities, and challenges for global Age-related Macular Degeneration (AMD)
  • Market Influencing Factors: To find out the factors which are affecting the market of global Age-related Macular Degeneration (AMD) among consumers.
  • Company Profiling: To provide a detailed insight into the major companies operating in the market. The profiling will include the financial health of the company's past 2-3 years with segmental and regional revenue breakup, product offering, recent developments, SWOT analysis, and key strategies.

Research Methodology

Our research methodology has always been the key differentiating reason which sets us apart in comparison from the competing organizations in the industry. Our organization believes in consistency along with quality and establishing a new level with every new report we generate; our methods are acclaimed and the data/information inside the report is coveted. Our research methodology involves a combination of primary and secondary research methods. Data procurement is one of the most extensive stages in our research process. Our organization helps in assisting the clients to find the opportunities by examining the market across the globe coupled with providing economic statistics for each and every region.  The reports generated and published are based on primary & secondary research. In secondary research, we gather data for global Market through white papers, case studies, blogs, reference customers, news, articles, press releases, white papers, and research studies. We also have our paid data applications which includes hoovers, Bloomberg business week, Avention, and others.

Data Collection

Data collection is the process of gathering, measuring, and analyzing accurate and relevant data from a variety of sources to analyze market and forecast trends. Raw market data is obtained on a broad front. Data is continuously extracted and filtered to ensure only validated and authenticated sources are considered. Data is mined from a varied host of sources including secondary and primary sources.

Primary Research

After the secondary research process, we initiate the primary research phase in which we interact with companies operating within the market space. We interact with related industries to understand the factors that can drive or hamper a market. Exhaustive primary interviews are conducted. Various sources from both the supply and demand sides are interviewed to obtain qualitative and quantitative information for a report which includes suppliers, product providers, domain experts, CEOs, vice presidents, marketing & sales directors, Type & innovation directors, and related key executives from various key companies to ensure a holistic and unbiased picture of the market. 

Secondary Research

A secondary research process is conducted to identify and collect information useful for the extensive, technical, market-oriented, and comprehensive study of the market. Secondary sources include published market studies, competitive information, white papers, analyst reports, government agencies, industry and trade associations, media sources, chambers of commerce, newsletters, trade publications, magazines, Bloomberg BusinessWeek, Factiva, D&B, annual reports, company house documents, investor presentations, articles, journals, blogs, and SEC filings of companies, newspapers, and so on. We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

Top-Down Approach & Bottom-Up Approach

In the top – down approach, the Global Batteries for Solar Energy Storage Market was further divided into various segments on the basis of the percentage share of each segment. This approach helped in arriving at the market size of each segment globally. The segments market size was further broken down in the regional market size of each segment and sub-segments. The sub-segments were further broken down to country level market. The market size arrived using this approach was then crosschecked with the market size arrived by using bottom-up approach.

In the bottom-up approach, we arrived at the country market size by identifying the revenues and market shares of the key market players. The country market sizes then were added up to arrive at regional market size of the decorated apparel, which eventually added up to arrive at global market size.

This is one of the most reliable methods as the information is directly obtained from the key players in the market and is based on the primary interviews from the key opinion leaders associated with the firms considered in the research. Furthermore, the data obtained from the company sources and the primary respondents was validated through secondary sources including government publications and Bloomberg.

Market Analysis & size Estimation

Post the data mining stage, we gather our findings and analyze them, filtering out relevant insights. These are evaluated across research teams and industry experts. All this data is collected and evaluated by our analysts. The key players in the industry or markets are identified through extensive primary and secondary research. All percentage share splits, and breakdowns have been determined using secondary sources and verified through primary sources. The market size, in terms of value and volume, is determined through primary and secondary research processes, and forecasting models including the time series model, econometric model, judgmental forecasting model, the Delphi method, among Flywheel Energy Storage. Gathered information for market analysis, competitive landscape, growth trends, product development, and pricing trends is fed into the model and analyzed simultaneously.

Quality Checking & Final Review

The analysis done by the research team is further reviewed to check for the accuracy of the data provided to ensure the clients’ requirements. This approach provides essential checks and balances which facilitate the production of quality data. This Type of revision was done in two phases for the authenticity of the data and negligible errors in the report. After quality checking, the report is reviewed to look after the presentation, Type and to recheck if all the requirements of the clients were addressed.

Frequently Asked Questions

Global Age-related Macular Degeneration (AMD) forecast period is 2024 - 2032
According to global Age-related Macular Degeneration (AMD) research, the market is expected to grow at a CAGR of ~ 8.21% over the next eight years.
The possible segments in global Age-related Macular Degeneration (AMD) are based on by Type, By End-User, Distribution Channel & by region.
The expected market size for Global Age-related Macular Degeneration (AMD) is USD 8.27 billion in 2023.
The major players in the market are Pfizer Inc., Novartis AG, Biogen, Amgen Inc., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc. and Bayer AG

Avail PDF Sample Reports